Infectious complications in patients with B-Lymphoid hematologic malignancy treated with CD19 chimeric antigen receptor T cell therapy.
Study #: IN20-01a
Study Status: Published
Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR.
Citation
Wudhikarn K, Herr MM, Chen M, Martens MJ, Baird JH, Gowda L, Rangarajan HG, Bilal AM, Kharfan-Dabaja MA, Williams KM, Ganguly S, Young JH, Sharma A, Fatobene G, Jain T, Kanakry CH, Modi D, Grover NS, Salem B, Batista MV, Vergidis P, Yin DE, Beitinjaneh AM, Kelkar AH, Nishihori T, Holter-Chakrabarty J, Gergis U, Smith M, El Boghdadly Z, Dandoy CE, Huppler AH, Murthy H, Perales MA, Chemaly RF, Hill JA, Riches M, Auletta JJ.
Blood Advances. 2025, May 28: (): . doi: 10.1182/bloodadvances.2025016141. Epub 2025, May 28. PMCID:PMC12607006.
PubMed
PMID: 40435511
Abstract
